| Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Doug Gentilcore - DANYELZA Business Unit Head Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Securities Mike Ulz - Morgan Stanley Justin Walsh - Jones Trading Li Watsek - Cantor John Newman - Canaccord Genuity Jeff Jones - Oppenheimer Bill Maughan - Clear Street David Nierengarten - Wedbush Kemp Dolliver - Brookline Capital Markets Chiara Montironi - Van Lanschot Kempen Alec Stranahan - Bank of America Operator Good morning, and welcome to Y-mAbs Therapeutics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-13 17:13:13 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates |
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.15 per share a year ago. |
zacks.com |
2025-05-13 12:45:44 |
Czytaj oryginał (ang.) |
| Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 |
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. |
globenewswire.com |
2025-05-13 11:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments |
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-13 10:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) |
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that naxitamab-gqgk (DANYELZA®) is recommended by the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for high-risk neuroblastoma. |
globenewswire.com |
2025-05-07 11:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 |
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. |
globenewswire.com |
2025-05-06 11:05:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline |
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:05:41 |
Czytaj oryginał (ang.) |
| Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting |
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL. |
globenewswire.com |
2025-04-27 19:00:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma |
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial evaluating the Company's Self-Assembly and Disassembly (“SADA”) Pre-targeted Radioimmunotherapy (“PRIT”) platform for the treatment of patients with relapsed or refractory non-Hodgkin Lymphoma (r/r NHL). This Phase 1 trial (Trial 1201) is a dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex. |
globenewswire.com |
2025-04-25 11:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity |
YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's main R&D focus, with crucial phase 1 readouts anticipated soon. Despite a net loss of $29.7 million, YMAB's $67.2 million cash position and steady naxitamab sales provide a cash runway into 2027. |
seekingalpha.com |
2025-04-11 20:35:35 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senior VP & Head of DANYELZA Business Unit Natalie Tucker - Radiopharmaceutical Business Unit Head Peter Pfreundschuh - CFO Conference Call Participants Alec Stranahan - Bank of America Michael Wolf - Morgan Stanley Jeff Jones - Oppenheimer Nicole Germino - Truist Li Watsek - Cantor Fitzgerald William Maughan - Clear Street Justin Walsh - JonesTrading Robert Burns - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Good morning and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the Fourth Quarter and Full Year 2024. |
seekingalpha.com |
2025-03-04 17:03:52 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates |
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-03-04 10:45:23 |
Czytaj oryginał (ang.) |
| Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments |
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZA Cash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024 Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-04 08:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications |
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrow |
globenewswire.com |
2025-03-03 09:30:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release |
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-25 13:00:29 |
Czytaj oryginał (ang.) |
| Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 |
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. |
globenewswire.com |
2025-02-20 18:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference |
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET. |
globenewswire.com |
2025-02-06 09:30:00 |
Czytaj oryginał (ang.) |
| YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for YmAbs Therapeutics (YMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-04 12:36:41 |
Czytaj oryginał (ang.) |
| YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
YmAbs Therapeutics (YMAB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-02-03 12:35:27 |
Czytaj oryginał (ang.) |
| Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting |
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American College of Nuclear Medicine (ACNM) Annual Meeting being held on January 30 to February 1, 2025 in Anaheim, California. |
globenewswire.com |
2025-01-31 09:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials |
YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. |
seekingalpha.com |
2025-01-24 19:57:21 |
Czytaj oryginał (ang.) |
| Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities |
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA |
globenewswire.com |
2025-01-10 11:26:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit |
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. |
globenewswire.com |
2025-01-10 09:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Provides Strategic Business Update and 2025 Priorities |
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA |
globenewswire.com |
2025-01-10 09:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. PT. |
globenewswire.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting |
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California. |
globenewswire.com |
2024-12-07 14:00:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference |
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that it will participate in Citi's 2024 Global Healthcare Conference. Members of the Y-mAbs management team will host one-on-one meetings at the conference on Wednesday, December 4, 2024 in Miami, FL. |
globenewswire.com |
2024-11-27 09:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates |
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago. |
zacks.com |
2024-11-08 10:45:26 |
Czytaj oryginał (ang.) |
| Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments |
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-08 08:35:00 |
Czytaj oryginał (ang.) |
| Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan |
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma. |
globenewswire.com |
2024-11-04 09:35:00 |
Czytaj oryginał (ang.) |
| Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know |
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-01 13:06:10 |
Czytaj oryginał (ang.) |
| Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast |
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. |
globenewswire.com |
2024-10-25 11:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Participate in Upcoming Investor Conferences in October |
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-10-01 11:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research |
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada. |
globenewswire.com |
2024-09-06 11:30:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Participate in Upcoming Investor Conferences in September |
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences: |
globenewswire.com |
2024-09-03 12:32:00 |
Czytaj oryginał (ang.) |
| Why Y-mAbs Therapeutics Stock Got Mashed on Monday |
The commercial-stage biotech took the wraps off its second-quarter results. Revenue was up on a year-over-year basis, but it fell short of analyst estimates -- as did net loss. |
fool.com |
2024-08-12 22:33:54 |
Czytaj oryginał (ang.) |
| Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade) |
YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. |
seekingalpha.com |
2024-08-12 16:08:04 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good morning, and welcome to Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the Second Quarter of 2024. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-12 15:20:27 |
Czytaj oryginał (ang.) |
| Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates |
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2024-08-12 12:40:48 |
Czytaj oryginał (ang.) |
| Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments |
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-08-12 10:30:00 |
Czytaj oryginał (ang.) |
| Y-mAbs to Participate in Upcoming Investor Conferences in August |
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-07 11:05:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast |
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. |
globenewswire.com |
2024-08-05 20:05:00 |
Czytaj oryginał (ang.) |
| Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB |
NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB): |
globenewswire.com |
2024-07-22 12:00:00 |
Czytaj oryginał (ang.) |
| Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer |
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. |
globenewswire.com |
2024-07-01 20:05:00 |
Czytaj oryginał (ang.) |